CL2004000392A1 - Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra - Google Patents

Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra

Info

Publication number
CL2004000392A1
CL2004000392A1 CL200400392A CL2004000392A CL2004000392A1 CL 2004000392 A1 CL2004000392 A1 CL 2004000392A1 CL 200400392 A CL200400392 A CL 200400392A CL 2004000392 A CL2004000392 A CL 2004000392A CL 2004000392 A1 CL2004000392 A1 CL 2004000392A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
compounds
trisustituidos
dislipidemia
oxazol
Prior art date
Application number
CL200400392A
Other languages
English (en)
Spanish (es)
Inventor
Kirk Glombik Heiner Fa Gretzke
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CL2004000392A1 publication Critical patent/CL2004000392A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CL200400392A 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra CL2004000392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
CL2004000392A1 true CL2004000392A1 (es) 2005-04-22

Family

ID=32920629

Family Applications (2)

Application Number Title Priority Date Filing Date
CL200400391A CL2004000391A1 (es) 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.
CL200400392A CL2004000392A1 (es) 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL200400391A CL2004000391A1 (es) 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.

Country Status (34)

Country Link
US (5) US7259177B2 (US07259177-20070821-C00075.png)
EP (3) EP1599455B1 (US07259177-20070821-C00075.png)
JP (3) JP2006519199A (US07259177-20070821-C00075.png)
KR (3) KR20050105492A (US07259177-20070821-C00075.png)
CN (3) CN100398526C (US07259177-20070821-C00075.png)
AR (3) AR043432A1 (US07259177-20070821-C00075.png)
AT (3) ATE435217T1 (US07259177-20070821-C00075.png)
AU (3) AU2004215673B2 (US07259177-20070821-C00075.png)
BR (3) BRPI0407907A (US07259177-20070821-C00075.png)
CA (3) CA2517381A1 (US07259177-20070821-C00075.png)
CL (2) CL2004000391A1 (US07259177-20070821-C00075.png)
CO (2) CO5690578A2 (US07259177-20070821-C00075.png)
DE (4) DE10308355A1 (US07259177-20070821-C00075.png)
DK (3) DK1599452T3 (US07259177-20070821-C00075.png)
EC (2) ECSP055985A (US07259177-20070821-C00075.png)
ES (3) ES2287700T3 (US07259177-20070821-C00075.png)
HR (3) HRP20050743A2 (US07259177-20070821-C00075.png)
IL (2) IL170314A (US07259177-20070821-C00075.png)
MA (3) MA27742A1 (US07259177-20070821-C00075.png)
MX (3) MXPA05008988A (US07259177-20070821-C00075.png)
NO (3) NO20054396L (US07259177-20070821-C00075.png)
OA (2) OA13034A (US07259177-20070821-C00075.png)
PA (1) PA8596801A1 (US07259177-20070821-C00075.png)
PE (3) PE20050292A1 (US07259177-20070821-C00075.png)
PL (3) PL377735A1 (US07259177-20070821-C00075.png)
PT (3) PT1599452E (US07259177-20070821-C00075.png)
RS (1) RS20050594A (US07259177-20070821-C00075.png)
RU (3) RU2005129995A (US07259177-20070821-C00075.png)
SA (1) SA04250153A (US07259177-20070821-C00075.png)
TN (2) TNSN05206A1 (US07259177-20070821-C00075.png)
TW (3) TW200500349A (US07259177-20070821-C00075.png)
UY (2) UY28209A1 (US07259177-20070821-C00075.png)
WO (3) WO2004076426A1 (US07259177-20070821-C00075.png)
ZA (2) ZA200505765B (US07259177-20070821-C00075.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
US8128969B2 (en) 2006-08-10 2012-03-06 Mimozax Co., Ltd. Hypoglycemic composition containing acacia bark derivative
JP5340287B2 (ja) 2007-08-16 2013-11-13 ソルヴェイ(ソシエテ アノニム) 4−フルオロ置換3−オキソ−アルカン酸のエステル類の調製方法
NZ587261A (en) * 2008-02-29 2012-05-25 Nissan Chemical Ind Ltd Process for producing thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116300352A (zh) 2017-12-13 2023-06-23 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DK0958296T3 (da) 1996-12-31 2003-08-18 Reddys Lab Ltd Dr Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
KR20010021936A (ko) 1997-07-16 2001-03-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
ES2261202T3 (es) * 1999-04-28 2006-11-16 Sanofi-Aventis Deutschland Gmbh Derivados de acido de triarilo como ligandos para el receptor ppar.
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
JP2002543200A (ja) 1999-04-30 2002-12-17 ニューロゲン コーポレイション 9H−ピリミド[4、5−b]インドール誘導体:CRF1特異性リガンド
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
WO2001009111A1 (en) 1999-07-29 2001-02-08 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
EP1218341B1 (de) 1999-09-01 2005-08-24 Aventis Pharma Deutschland GmbH Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CZ20021902A3 (cs) 1999-12-03 2002-11-13 Astrazeneca Ab Krystalická forma kyseliny (S)-2-ethoxy-3-[4-(2-{4-methansulfonyloxyfenyl}ethoxy)fenyl]propanové
EP2266665B1 (en) 2000-03-31 2016-05-11 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
HUP0300475A3 (en) 2000-04-25 2004-10-28 Kyorin Seiyaku Kk Novel stable crystal of thiazolidinedione derivative and process for producing the same
AU5257401A (en) 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
EP1280777B1 (en) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
EE200200634A (et) * 2000-06-09 2004-04-15 Aventis Pharma Deutschland Gmbh Atsüülfenüülkarbamiidi derivaadid, nende saamine ja kasutamine veresuhkrut alandava ravimi valmistamiseks ning neid sisaldav ravim
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
ES2288982T3 (es) 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
DE60128239T2 (de) * 2000-08-23 2008-01-10 Eli Lilly And Co., Indianapolis Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002046146A1 (fr) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU2002216097B2 (en) 2000-12-21 2006-09-07 Sanofi-Aventis Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
IL156505A0 (en) * 2000-12-25 2004-01-04 Ono Pharmaceutical Co Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
EP1360172A1 (en) * 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
MXPA03010903A (es) * 2001-06-07 2004-02-17 Lilly Co Eli Moduladores de receptores activados por el proliferador de peroxisomas.
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
BR0212158A (pt) 2001-08-31 2004-07-13 Aventis Pharma Gmbh Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar
JP2005517008A (ja) 2002-02-05 2005-06-09 イーライ・リリー・アンド・カンパニー Pparモジュレーターとして用いるためのウレアリンカー誘導体
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
EP1599455A1 (de) 2005-11-30
NO20054408D0 (no) 2005-09-22
AU2004215673B2 (en) 2009-10-01
DK1599453T3 (da) 2009-08-24
TNSN05206A1 (en) 2007-06-11
KR20050106461A (ko) 2005-11-09
PE20050292A1 (es) 2005-05-24
US7335671B2 (en) 2008-02-26
CA2517386A1 (en) 2004-09-10
TW200500349A (en) 2005-01-01
US20040209920A1 (en) 2004-10-21
AR043433A1 (es) 2005-07-27
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
CN1753879A (zh) 2006-03-29
TW200510352A (en) 2005-03-16
MA27736A1 (fr) 2006-02-01
ATE435217T1 (de) 2009-07-15
DK1599452T3 (da) 2007-10-01
AU2004215672A1 (en) 2004-09-10
RU2005129992A (ru) 2006-02-10
AR043427A1 (es) 2005-07-27
CL2004000391A1 (es) 2005-01-07
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
DE10308355A1 (de) 2004-12-23
US7259177B2 (en) 2007-08-21
UY28210A1 (es) 2004-09-30
MA27737A1 (fr) 2006-02-01
ES2329366T3 (es) 2009-11-25
ATE430738T1 (de) 2009-05-15
ES2287700T3 (es) 2007-12-16
CN1753881A (zh) 2006-03-29
AU2004215673A1 (en) 2004-09-10
MA27742A1 (fr) 2006-02-01
ECSP055986A (es) 2006-01-16
PE20040959A1 (es) 2005-01-17
PT1599453E (pt) 2009-07-14
PT1599455E (pt) 2009-09-29
ZA200505765B (en) 2006-05-31
US20050101637A1 (en) 2005-05-12
NO20054398D0 (no) 2005-09-22
CO5690580A2 (es) 2006-10-31
CA2517381A1 (en) 2004-09-10
BRPI0407758A (pt) 2006-02-14
JP2006519194A (ja) 2006-08-24
AU2004215677B2 (en) 2010-01-07
TNSN05204A1 (en) 2007-06-11
DE502004009690D1 (de) 2009-08-13
JP2006519199A (ja) 2006-08-24
AR043432A1 (es) 2005-07-27
US20050215596A1 (en) 2005-09-29
MXPA05008995A (es) 2005-10-18
CN100398526C (zh) 2008-07-02
WO2004076428A1 (de) 2004-09-10
DE502004004139D1 (de) 2007-08-02
OA13035A (en) 2006-11-10
KR20050105492A (ko) 2005-11-04
RS20050594A (en) 2007-12-31
PE20050293A1 (es) 2005-05-24
PL378437A1 (pl) 2006-04-03
ES2326418T3 (es) 2009-10-09
CN100439347C (zh) 2008-12-03
BRPI0407907A (pt) 2006-02-14
KR20050106462A (ko) 2005-11-09
CN1756748A (zh) 2006-04-05
DK1599455T3 (da) 2009-11-09
PL377735A1 (pl) 2006-02-20
PL378130A1 (pl) 2006-03-06
EP1599452B1 (de) 2007-06-20
AU2004215672B2 (en) 2010-01-07
DE502004009453D1 (de) 2009-06-18
AU2004215677A1 (en) 2004-09-10
US7365084B2 (en) 2008-04-29
NO20054396D0 (no) 2005-09-22
ZA200505768B (en) 2005-11-23
PT1599452E (pt) 2007-09-12
CA2516620A1 (en) 2004-09-10
MXPA05008951A (es) 2005-11-04
ECSP055985A (es) 2006-01-16
WO2004076426A1 (de) 2004-09-10
TW200508210A (en) 2005-03-01
CO5690578A2 (es) 2006-10-31
UY28209A1 (es) 2004-09-30
SA04250153A (ar) 2005-12-03
CN100439345C (zh) 2008-12-03
EP1599455B1 (de) 2009-07-01
JP2006519193A (ja) 2006-08-24
OA13034A (en) 2006-11-10
RU2005130002A (ru) 2006-01-27
US20080167354A1 (en) 2008-07-10
EP1599453B1 (de) 2009-05-06
US20080015238A1 (en) 2008-01-17
NO20054396L (no) 2005-11-11
RU2005129995A (ru) 2006-01-27
EP1599453A1 (de) 2005-11-30
ATE365159T1 (de) 2007-07-15
EP1599452A1 (de) 2005-11-30
HRP20050744A2 (en) 2006-09-30
IL170314A (en) 2010-11-30
WO2004076427A1 (de) 2004-09-10
HRP20050742A2 (en) 2006-09-30
MXPA05008988A (es) 2005-10-18
NO20054398L (no) 2005-11-02
US7872034B2 (en) 2011-01-18
BRPI0407814A (pt) 2006-02-14

Similar Documents

Publication Publication Date Title
CL2004000392A1 (es) Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra
BRPI0311275A2 (pt) "composições de fenofibrato estáveis para administração oral, bem como uso das mesmas"
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
DE60138872D1 (de) Azetidinderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
CL2007001915A1 (es) Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
BRPI0807290A2 (pt) "composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma"
CL2004000889A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
EE200300080A (et) Polüarüülkarboksamiidühendid, nende valmistamine ja kasutamine lipiiditaset alandavate toimeainetena ning neid sisaldav farmatseutiline kompositsioon
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
BR9711098B1 (pt) compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
ATE380023T1 (de) Orale feste pharmazeutische zusammensetzungen zur ph-abhängig mehrphasigen freisetzung
IL183982A0 (en) Controlled release formulation for oral administration for treating diabetes containing metformin and methods for the preparation thereof
EE200300046A (et) Asabitsüklilised ühendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EE05269B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
CL2008003153A1 (es) Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
FR2861074B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
BRPI0415825A (pt) novos derivados de tetrahidroespiro{piperidino-2,7'-pirrol[3,2b]piridina } e novos derivados de indol úteis no tratamento de distúrbios relacionados ao receptor 5-ht6
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
DK1119557T3 (da) Indeno-, naphto- og benzocyclohepta-dihydrothiazolderivater, fremstilling deraf og anvendelse deraf som anorektiske medikamenter
HUP0204557A3 (en) Benzazole derivatives, their use as jnk modulators, their preparation and pharmaceutical compositions containing them
CL43489B (es) Compuestos derivados de difenilazetidinona y su sal farmaceuticamente aceptable; composicion faramceutica; compuestos intermediarios; procedimiento para preparar la composicion farmaceutica; y uso de los compuestos para tratar la hiperlipidemia, sint
ITMI20021427A0 (it) Composizioni per uso nell'alimentazione animale comprendente una matrice a rilascio controllato procedimento di preparazione e relativo impi
EE200200399A (et) Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon